Li Jianing, Li Shuo, Yu Ling, Wei Jin, Sun Hongwei, Yang Caixia, Tan Hongyu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing, China.
Pain Physician. 2022 Mar;25(2):E385-E396.
Postoperative pain increases patients' risk and opioids remain the main analgesics to relieve it. However, improper use of opioids causes many side effects and identification of suitable preoperative biomarkers that predict postoperative opioid consumption may aid clinicians in improving analgesic strategies for patients. The activity of metabolites modulates multiple phenotypes and can function as biomarkers for disease prediction and diagnosis.
In this study, we explore whether preoperative serum metabolites are associated with postoperative opioid consumption in gastric cancer patients by extreme phenotype sampling.
This was a case-control, observational study.
This study was conducted at Beijing Cancer Hospital.
One hundred and sixty-nine gastric cancer patients participated in this study. After exclusion of 51 patients, postoperative pain intensity and opioid consumption data of 118 patients were collected. Patients were sorted by gender and classified into 2 groups based on opioid consumption during the 24h postoperative period. Patients in the sufentanil high consumption (SHC) group and patients in the sufentanil low consumption (SLC) group were ranked in the top or bottom 30% of sufentanil consumption, respectively. Untargeted metabolomic analysis of preoperative serum samples from both groups was performed by ultra-performance liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and orthogonal partial least square discriminant analysis. Allele frequencies of DAO rs10156191 and MAOB rs1799836 SNPs in both groups were detected by Sanger sequencing.
Thirty-five metabolites in preoperative serum were significantly different between the SLC and SHC groups. Hydrogen phosphate had the highest area under the curve in a ROC analysis (0.98), suggesting that it may serve as a predictive biomarker for postoperative opioid consumption. Differential metabolites unique to the male and female subgroups were also identified. Histidine metabolism was the most altered pathway between the SLC and SHC groups. There were no significant differences in the allele frequencies of 2 SNPs associated with histamine degradation; however, 2 metabolites of histamine degradation, imidazole-4-acetaldehyde, and methylimidazole acetaldehyde, showed different trends in the 2 groups.
Our study was restricted to gastric cancer patients with strict exclusion criteria, which may limit the generalizability to other groups.
Preoperative serum metabolites were associated with postoperative opioid consumption. Different efficiencies of histamine degradation may be one cause of the variable sensitivity of patients to acute pain and warrants further study.
术后疼痛会增加患者风险,阿片类药物仍是缓解疼痛的主要镇痛药。然而,阿片类药物使用不当会引发多种副作用,识别合适的术前生物标志物以预测术后阿片类药物消耗量,可能有助于临床医生改进对患者的镇痛策略。代谢物的活性可调节多种表型,并可作为疾病预测和诊断的生物标志物。
在本研究中,我们通过极端表型抽样,探究胃癌患者术前血清代谢物与术后阿片类药物消耗量之间是否存在关联。
这是一项病例对照观察性研究。
本研究在北京肿瘤医院开展。
169例胃癌患者参与本研究。排除51例患者后,收集了118例患者的术后疼痛强度和阿片类药物消耗量数据。根据性别对患者进行分类,并根据术后24小时内的阿片类药物消耗量分为2组。舒芬太尼高消耗(SHC)组和舒芬太尼低消耗(SLC)组患者分别在舒芬太尼消耗量最高或最低的30%范围内。通过超高效液相色谱-质谱/质谱联用(LC-MS/MS)和正交偏最小二乘判别分析,对两组患者术前血清样本进行非靶向代谢组学分析。通过桑格测序检测两组中DAO rs10156191和MAOB rs1799836单核苷酸多态性(SNP)的等位基因频率。
术前血清中的35种代谢物在SLC组和SHC组之间存在显著差异。在ROC分析中,磷酸氢盐的曲线下面积最高(0.98),表明它可能作为术后阿片类药物消耗量的预测生物标志物。还确定了男性和女性亚组特有的差异代谢物。组氨酸代谢是SLC组和SHC组之间变化最大的途径。与组胺降解相关的2个SNP的等位基因频率没有显著差异;然而,组胺降解的2种代谢物,咪唑-4-乙醛和甲基咪唑乙醛,在两组中呈现不同趋势。
我们的研究仅限于具有严格排除标准的胃癌患者,这可能会限制其对其他群体的普遍性。
术前血清代谢物与术后阿片类药物消耗量相关。组胺降解效率不同可能是患者对急性疼痛敏感性差异的一个原因,值得进一步研究。